Neurological disorders—such as epilepsy, multiple sclerosis and Parkinson’s disease—inflict great pain and suffering on patients and their families, and every year costs the U.S. economy billions of dollars. Biopharmaceutical research companies are developing 444 new medicines to prevent and treat neurological disorders.
Landing Page: America’s biopharmaceutical research companies are developing 444 new medicines to prevent and treat neurological disorders, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).
There are more than 600 neurological disorders that strike millions of Americans each year. These diseases and disorders inflict great pain and suffering on millions of patients and their families, and cost the U.S. economy billions of dollars annually. They range from well-known disorders such as epilepsy, multiple sclerosis and Parkinson’s disease, to more obscure conditions such as Duchenne muscular dystrophy and Friedreich’s ataxia.
“Despite the incredible complexity of neurological disorders, biopharmaceutical scientists have delivered significant advances for patients in recent years, including new medicines for multiple sclerosis and Huntington’s disease,” said PhRMA President and CEO John J. Castellani. “The nearly 450 medicines in the pipeline have the potential to bring us ever closer to our shared goal of providing better health and longer lives to patients facing these debilitating disorders.”